• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫疗法可减少抗原诱导的嗜酸性粒细胞向鼻腔的迁移。

Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.

作者信息

Furin M J, Norman P S, Creticos P S, Proud D, Kagey-Sobotka A, Lichtenstein L M, Naclerio R M

机构信息

Department of Medicine (Division of Clinical Immunology) Johns Hopkins University School of Medicine, Baltimore, Md.

出版信息

J Allergy Clin Immunol. 1991 Jul;88(1):27-32. doi: 10.1016/0091-6749(91)90297-2.

DOI:10.1016/0091-6749(91)90297-2
PMID:2071783
Abstract

We investigated the effect of immunotherapy (IT) on eosinophil (EOS) migration into the nasal cavity after nasal provocation with ragweed antigen and during seasonal exposure. In the first study, three groups of subjects participated: one group with no treatment (N = 19), one group with 10 months of IT, reaching maintenance at 2 micrograms of Amb a I (antigen E) (N = 15), and one group with 22 months of IT, reaching maintenance at 24 micrograms of Amb a I (N = 10). The percent of EOSs in nasal lavages performed during December before and 24 hours after nasal challenge with ragweed extract was determined. No significant difference between groups existed before challenge. The no treatment group demonstrated a significant increase in the percent of EOSs from 26% to 69.5% (p less than 0.008), whereas the treated groups demonstrated no significant change. In the second study, 45 patients were divided into four groups based on maintenance dose in micrograms of Amb a I and duration of treatment: (1) no treatment (N = 15), (2) 1 year at 2 micrograms (N = 13), (3) 2 years at 2 micrograms (N = 11), and (4) 3 years at 24 micrograms (N = 9). Nasal mucosal brushings were done during the ragweed season. A significantly smaller percentage of EOSs in 3-year IT-treated individuals was obtained compared to the control group (18 versus 8.4; p less than 0.04). The smaller dose of IT, regardless of duration, did not reveal a reduction compared to that in the no-treatment group.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们研究了免疫疗法(IT)对豚草抗原鼻腔激发后以及季节性暴露期间嗜酸性粒细胞(EOS)迁移至鼻腔的影响。在第一项研究中,三组受试者参与:一组未接受治疗(N = 19),一组接受10个月的IT治疗,维持剂量为2微克的Amb a I(抗原E)(N = 15),另一组接受22个月的IT治疗,维持剂量为24微克的Amb a I(N = 10)。测定了12月豚草提取物鼻腔激发前及激发后24小时鼻腔灌洗中EOS的百分比。激发前各组间无显著差异。未治疗组EOS百分比从26%显著增加至69.5%(p < 0.008),而治疗组无显著变化。在第二项研究中,45名患者根据Amb a I的维持剂量(微克)和治疗持续时间分为四组:(1)未治疗(N = 15),(2)2微克治疗1年(N = 13),(3)2微克治疗2年(N = 11),(4)24微克治疗3年(N = 9)。在豚草季节进行鼻黏膜刷检。与对照组相比,接受3年IT治疗的个体中EOS的百分比显著更低(18对8.4;p < 0.04)。无论治疗持续时间如何,较小剂量的IT与未治疗组相比未显示出降低。(摘要截短于250字)

相似文献

1
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.免疫疗法可减少抗原诱导的嗜酸性粒细胞向鼻腔的迁移。
J Allergy Clin Immunol. 1991 Jul;88(1):27-32. doi: 10.1016/0091-6749(91)90297-2.
2
The nasal response to histamine challenge: effect of the pollen season and immunotherapy.
J Allergy Clin Immunol. 1992 Jul;90(1):85-91. doi: 10.1016/s0091-6749(06)80014-x.
3
A double-blind study of the discontinuation of ragweed immunotherapy.豚草免疫疗法停药的双盲研究。
J Allergy Clin Immunol. 1997 Sep;100(3):293-300. doi: 10.1016/s0091-6749(97)70240-9.
4
Responses to ragweed-pollen nasal challenge before and after immunotherapy.
J Allergy Clin Immunol. 1989 Aug;84(2):197-205. doi: 10.1016/0091-6749(89)90325-4.
5
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.Amb a 1免疫刺激寡脱氧核苷酸共轭免疫疗法可减轻鼻腔炎症反应。
J Allergy Clin Immunol. 2004 Feb;113(2):235-41. doi: 10.1016/j.jaci.2003.11.001.
6
Efficacy and safety of oral immunotherapy with short ragweed extract.短豚草提取物口服免疫疗法的疗效与安全性。
Ann Allergy Asthma Immunol. 1997 Jun;78(6):573-80. doi: 10.1016/S1081-1206(10)63218-8.
7
Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis.Amb a 1免疫刺激寡脱氧核苷酸共轭免疫疗法可增加变应性鼻炎患者鼻黏膜中的CD4+CD25+ T细胞。
Allergol Int. 2008 Dec;57(4):377-81. doi: 10.2332/allergolint.O-07-528. Epub 2008 Dec 1.
8
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.使用豚草Toll样受体9激动剂疫苗治疗过敏性鼻炎的免疫疗法。
N Engl J Med. 2006 Oct 5;355(14):1445-55. doi: 10.1056/NEJMoa052916.
9
The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.草花粉变应原免疫疗法对变应性鼻炎儿童临床和免疫学参数的影响。
Pediatr Allergy Immunol. 2006 Sep;17(6):396-407. doi: 10.1111/j.1399-3038.2006.00442.x.
10
Unilateral nasal allergic reactions increase bilateral sinus eosinophil infiltration.单侧鼻过敏反应会增加双侧鼻窦嗜酸性粒细胞浸润。
J Appl Physiol (1985). 2013 Nov 1;115(9):1262-7. doi: 10.1152/japplphysiol.00547.2013. Epub 2013 Aug 22.

引用本文的文献

1
IgE versus IgG and IgA: Differential roles of allergen-specific antibodies in sensitization, tolerization, and treatment of allergies.免疫球蛋白E与免疫球蛋白G和免疫球蛋白A:变应原特异性抗体在过敏致敏、免疫耐受及治疗中的不同作用
Immunol Rev. 2024 Nov;328(1):314-333. doi: 10.1111/imr.13386. Epub 2024 Sep 16.
2
Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.变应原免疫治疗中的生物标志物:聚焦嗜酸性粒细胞炎症。
Asia Pac Allergy. 2024 Mar;14(1):32-38. doi: 10.5415/apallergy.0000000000000129. Epub 2023 Dec 18.
3
KAAACI Guidelines for Allergen Immunotherapy.
KAAACI变应原免疫治疗指南。
Allergy Asthma Immunol Res. 2023 Nov;15(6):725-756. doi: 10.4168/aair.2023.15.6.725.
4
Immunology of allergen immunotherapy.变应原免疫疗法的免疫学
Immunother Adv. 2022 Nov 25;2(1):ltac022. doi: 10.1093/immadv/ltac022. eCollection 2022.
5
Adaptogenic and immunomodulatory activity of Virgozest - An ayurvedic proprietary formulation.维尔戈泽斯特的适应原性和免疫调节活性——一种阿育吠陀专利配方。
Ayu. 2020 Oct-Dec;41(4):255-261. doi: 10.4103/ayu.ayu_57_21. Epub 2022 Jun 3.
6
Mechanisms of Allergen Immunotherapy in Allergic Rhinitis.变应性鼻炎的变应原免疫治疗机制
Curr Allergy Asthma Rep. 2020 Dec 12;21(1):2. doi: 10.1007/s11882-020-00977-7.
7
Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. Toll 样受体激动剂作为变应原免疫治疗的佐剂。
Front Immunol. 2020 Nov 12;11:599083. doi: 10.3389/fimmu.2020.599083. eCollection 2020.
8
EAACI Allergen Immunotherapy User's Guide.EAACI 过敏原免疫治疗用户指南。
Pediatr Allergy Immunol. 2020 May;31 Suppl 25(Suppl 25):1-101. doi: 10.1111/pai.13189.
9
Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies.变应原特异性免疫治疗过敏性鼻炎和食物过敏的机制。
Biosci Rep. 2020 Apr 30;40(4). doi: 10.1042/BSR20200256.
10
HDAC inhibitor sodium butyrate prevents allergic rhinitis and alters lncRNA and mRNA expression profiles in the nasal mucosa of mice.组蛋白去乙酰化酶抑制剂丁酸钠预防变应性鼻炎并改变小鼠鼻黏膜中的长链非编码 RNA 和信使 RNA 表达谱。
Int J Mol Med. 2020 Apr;45(4):1150-1162. doi: 10.3892/ijmm.2020.4489. Epub 2020 Feb 5.